Mabey and Ricci will demonstrate that information-seeking behavior is a significant predictor of future actions, brand choice, early adoption, and decision making.

They will present three information-seeking behavior segment templates, each requiring a different communication strategy and use real world pharmaceutical examples to discuss how they can be used to maximize brand impact.

Where: 2012 PMRG Annual National Conference at the JW Grande Lakes in Orlando.
When: March 25-27, 2012.

Attendees will learn:
* A new way to leverage information-seeking behavior to drive brand communication strategy
* Examples of three segments of information-seeking behavior to use as beginning templates
* Best practices for developing information-seeking, segment-specific communication strategies

The PMRG 2012 Annual National Conference, “Rev Up Your Innovation Engine,” is a three-day conference packed with 21 insightful presentations and breakout sessions, featuring 16 manufacturers among a slate of expert presenters, designed to help marketing researchers harness both the practical – and the personal – power of innovation.

About CMI:
CMI is a full-service marketing research company that combines comprehensive market research expertise with marketing insight to provide clients with a deep understanding of their customers by identifying the choices they make and why. Since 1989, CMI has delivered unique solutions to uncover opportunities, optimize marketing strategies, and improve performance for clients in consumer and B2B markets. CMI’s experienced team of market research consultants leverages a wide range of qualitative and quantitative methods and technologies to translate research into insights and insights into actions. CMI serves primarily Fortune 1000 clients. For more information about CMI, visit www.cmiresearch.com .

About Pfizer Inc.:
At Pfizer (NYSE:PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com .

News Source: CMI :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

This new skin care product is based on a combination of stem cell and infrared nanotechnology. It is the most potent skin care formula that combines gene therapy (FGF-1 peptide) and Far Infrared Powder (FIR) to rejuvenate and restore the beauty of damaged or aging skin.

This new Elixir of Life Serum helps to activate the body’s stem cells to repair damaged tissue and skin regeneration.

“Results are proven. The FGF-1 peptide – the stem cell activator – helps to increase new skin cell growth at least 10-20 times faster than with other skin care products,” says Nataly Giter, founder, E’shee Clinical Esthetic.

Elixir of Life is ideal for people with circulation problems due to external factors such as pollution, and physical problems due to illness, medications or smoking. It works to repair dark circles and broken capillaries; delays the overall skin aging process through skin repair and re-growth; and also works to properly heal and repair scar tissue.

People of all ages – men and women – will see physical results within 30 days. Skin will be healthier and firmer with a smoother and more even skin tone.

“Ultimately, this new product helps to restore blood flow; aids with toxin removal; repairs broken capillaries; and reverses skin damage. We are very excited to offer this to anyone wishing to dramatically improve their skin care,” says Giter.

About E’shee Clinical Esthetic:
E’shee was launched in 2009 by Nataly Giter, a hands-on skin care professional with more than 20 years of experience. Through research and practical experience, she learned about the most effective ingredients for advanced skin care and became associated with Dr. Chiu, a professor from Ohio University and the first global pioneer to clone the human FGF-1 gene.

Together with Dr. Chiu and their combined connections to industry professionals, they utilized FGF-1 to create an extraordinary anti-aging product line, using 99 percent pure FGF-1 peptide – the best quality available outside of the human body.

For more information on E’shee Clinical Esthetic, visit: www.esheeesthetic.com or www.esheeesthetic.com/wordpress/ .

* Photo 300dpi download for media: Send2Press.com/mediaboom/12-0221-eshee_300dpi.jpg .
* Photo Caption: Elixir of Life Serum.

News Source: E’shee Clinical Esthetic :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

ProKera(R) is a unique treatment option for patients presenting with corneal abrasions, scarring, erosions, corneal scars, chemical burns, corneal defects, partial limbal stem cell deficiencies, high-risk corneal transplants, Stevens – Johnson syndrome, and many other ocular surface conditions which may require corneal surgery or a corneal transplant. Sutureless and adhesiveless, ProKera(R) is a safe and effective method to promote healing and reconstruction of the ocular surface and orbit with minimal side effects.

ProKera(R) is similar to a contact lens and is made by placing a piece of amniotic membrane tissue in between two rings made out of a clear, flexible material. The membrane is thin and clear, like the tissue on the surface of the eye and protects the eye’s damaged tissue while inserted. The ProKera(R) device can remain in the eye for up to 30 days. However, it should facilitate healing of most defects within 5-10 days, at which point the membrane in the device will naturally dissolve and the ring set can be removed by an eye surgeon.

The healing properties of ProKera(R) deliver natural biological and therapeutic actions inherent in amniotic tissue to help damaged eye surfaces heal faster. Eyes treated with ProKera(R) heal faster, with less scarring and inflammation. Moreover, it reduces chances of the formation of abnormal blood vessels and induces less pain or discomfort to the patient.

“ProKera allows me to provide my patients with exceptional clinical results safely and effectively, without surgery,” said Dr. Mary Davidian. “In addition, the ProKera device is now configured and packaged much like a contact lens, which enables easy insertion right here in our office, hospital bedside, or following other surgical procedures. I have been using ProKera in the operating room for several years and I was delighted when it was officially approved by Medicare recently for use as an office procedure rather than an operating room procedure.”

Considered a leading expert in cataract, corneal treatment and surgery, Dr. Davidian frequents national conferences on ophthalmology. She has lectured to other ophthalmologists on the proper use of ProKera(R) and proper diagnosis, addressing the conditions under which a patient can benefit the most from this device.

“I think of it as a magic Band-Aid,” said Dr. Davidian. “As a corneal specialist, I see many of patients with corneal damage, including patients referred to me by my colleagues. ProKera(R) allows me to provide patients with a unique alternative to surgery which, in many cases, helps them with a much quicker and less painful recovery.”

Dr. Mary Davidian, founder and Medical Director of Highland Ophthalmology Associates, LLC, has been living in and serving the greater Hudson Valley community since 1997. Dr. Davidian is a fellowship trained corneal specialist. She is a member of the American Academy of Ophthalmology (AAO), The American Society of Cataract and Refractive Surgery (ASCRS), the New York Keratorefractive Surgery Society, the New York Intraocular Lens Implant (NYIOL) Society, and the New York State Ophthalmological Society (NYSOS) in which she has served on the Board of Directors.

Dr. Davidian is board certified by the American Board of Ophthalmology and serves as an Associate Adjunct Professor at the New York Eye and Ear Infirmary and the New York Medical College.

Call (845) 562-0138 today for your first consultation with Dr. Davidian. For more information about ProKera(R), visit www.highlandophthalmology.com .

The Bio-Tissue ProKera(R) website is www.biotissue.com .

ProKera(R) is a registered trademark of Bio-Tissue, Inc.

News Source: Highland Ophthalmology Associates :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

“With two options for immunotherapy, we can now better tailor treatment to the temperament of the patient, and lifestyle of the pet owner,” says Dr. Susan Keesee, Chief Scientific Officer at Bio-Medical Services. “This will allow more patients to receive the allergy treatment they need.”

Bio-Medical Services has been following the use of sublingual immunotherapy (allergy drops) in humans as an alternative method for administering allergy treatment. Allergy drops have been widely used in Europe, and are now gaining favor in the U.S.; the first randomized trial in humans was conducted in 1986 with proven efficacy. In a 2010 study conducted by the University of Wisconsin Veterinary School, sublingual immunotherapy was shown to be effective in reducing symptoms and allergen-specific IgE levels in dogs as well (*Note 1). Allergy drops are now being offered for canine allergy treatment by a select few veterinary teaching hospitals. “Because of its proven efficacy in humans, and early success shown in canines, we feel confident that sublingual immunotherapy is a safe and effective treatment modality,” says Keesee.

As the gap between human and veterinary medicine narrows, Bio-Medical Services remains in the forefront of serum allergy testing and treatment, providing the most current and effective medicine for pet allergy patients. Bio-Medical Services has achieved many “firsts” in the care of pet allergies. They were the first to offer ELISA serum testing for canine, feline and equine patients.

In 2004, Bio-Medical services was the first to introduce the practice of separating mold, mite and insect allergens into separate treatment from pollen, fiber and epithelia allergens to the veterinary field – following the convention used in human allergy treatment. Currently, Bio-Medical Services is the only laboratory to offer five treatment protocols based on the patient’s age, weight, breed, species, and clinical history. And now with two options for administering immunotherapy, patients receive even more customized and effective care for pet allergies.

About Bio-Medical Services:
Bio-Medical Services is a veterinary reference laboratory specializing in allergy testing and treatment for dogs, cats and horses. Founded in 1989, Bio-Medical Services was the first laboratory to develop a commercial application for in vitro allergy diagnostics in the veterinary industry. Bio-Medical Services is based in Austin, TX. Visit http://www.bmslab.com to learn more.

*(NOTE 1) D.J DeBoer, 2010. Pilot trial of sublingual immunotherapy (SLIT) in mite-sensitive atopic dogs. Veterinary Dermatology: Volume 21, Number 3, Page 325.

MEDIA CONTACT:
Jenna Overbeck
Steel Brand Communications
800.681.8809 x102
direct: 512-354-1120
Jenna.Overbeck@Steelbranding.com.

News Source: Bio-Medical Services :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The paper, “Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity,” was the product of a collaboration between RBC and the Fox Chase Cancer Center of Philadelphia. The article is currently available online and will be in the November 2011 print edition of Nature Biotechnology.

The data set from the study can be viewed at reactionbiology.com/webapps/kir/.

To perform the study, the researchers selected 178 small molecule kinase inhibitors, including FDA-approved drugs, clinical trial agents and research compounds. These compounds, known to include inhibitors of all major kinase families, were then systematically profiled against 300 human wild-type kinases, also representing all major kinase families. Quantitative analysis of the results revealed that many well-studied kinase inhibitors had significant and hitherto unknown off-target activities. In other words, not only did they inhibit enzymes belonging to the same subfamilies as their putative targets, but they also inhibited kinases from completely different families. 6 compounds, in particular, had off-target inhibition levels stronger than the intended target. These results emphasize the importance of profiling compounds against a broad kinase panel before proceeding to animal studies or clinical trials.

As part of their analysis of the new data set, the authors introduced the concept of a “uni-specific kinase inhibitor.” A compound with a high “uni-specificity” score is one whose inhibition of one particular kinase greatly exceeds its inhibition of the second most inhibited kinase, a stringent measure of compound selectivity. This approach helped to identify many potential lead compounds for “orphan” kinases, enzymes for which few inhibitors currently exist. In a parallel analysis of the data set, the researchers sought compounds whose primary target was a cancer-relevant kinase, but which could also inhibit a limited number of cancer-relevant kinases outside the primary target’s family. Such an approach can serve as the starting point for developing new multi-targeted kinase inhibitors and therapeutics.

“Kinase drug discovery remains a significant interest for both our academic customers and those in the pharmaceutical industry,” said Haiching Ma, Ph.D., Chief Technology Officer of RBC and one of the lead authors. “In the past decade, a large number of kinase inhibitors have been synthesized and published. However, there is no study trying to understand how these compounds interact with a large panel of kinases, especially using the activity-based assay formats used by majority of the kinase research labs. Applying the low-cost, high-throughput HotSpot platform, RBC has created the most reliable kinome-inhibitor database that a ‘gold standard’ radiometric assay format can produce.”

Dr. Ma continued, “This data set will not only help drug discovery activity in the industry, but also provide guidance for selecting the right tool compounds for use in routine kinase biology studies. RBC’s HotSpot provides a vital tool to evaluate these potential drug candidates.”

To date, RBC has developed and optimized assays for over 400 human kinases, including atypical kinases, mutants and lipid kinases that are important drug targets. “RBC is the market leader in providing activity-based screening and profiling. The panel we have collected has 100 more enzymes than most of our competitors,” said Mr. Matthew Oristano, Chairman of RBC. “With this continually growing panel of kinases, we can offer scientists a better understanding of their compounds and reduce the failure rate in future clinical trials. This publication has clearly demonstrated the value of including kinome-wide profiling as an integral part of compound lead validation.”

About Reaction Biology Corp.:
Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With over 400 kinases, RBC’s coverage of the kinome is the broadest in the industry for enzyme activity assays. Using its proprietary HotSpot(SM) technology and other innovations, RBC is also expanding its services to cover a broad range of epigenetic regulatory enzymes, including HDACs, HATs, HMTs, DNMTs, demethylases and epigenetic readers. RBC provides its services to over 200 customers worldwide, including large pharmaceutical, biotech, government and academic labs.

For more information, visit: www.reactionbiology.com.

HotSpot is a service mark of Reaction Biology Corp.

News Source: Reaction Biology Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The Missouri Senate overwhelmingly passed the Made in Missouri Jobs Package with a strong, bipartisan vote on Wednesday, September 14.

Soy Labs, LLC, the premier ingredient supplier delivering high-quality soy ingredients to leading health supplement formulators and manufacturers in the nutrition industry, and managing tenant of the Missouri Plant Science Center (MPSC), is seen for its technological and entrepreneurial thinking that is positioned to spur innovation and economic development in Missouri.

While touring the facility with Ryan Schmidt, Soy Labs president and other Soy Labs executives, Nixon discussed how MOSIRA and the Made in Missouri Jobs Package will create jobs while ensuring continued fiscal discipline and accountability with taxpayer resources.

“By embracing technology and showing the partnership between higher education, technology and entrepreneurship, it clearly will give us the capacity for the long term future,” Nixon said.

Soy Labs relocated from Fairfield, CA, last year, to be the managing tenant of the Missouri Plant Science Center, which is a joint venture of the Missouri Technology Corporation (MTC), the University of Missouri System and the city of Mexico, Mo.

The 25,000 square-foot Missouri Plant Science Center is a shared-use facility where researchers work alongside business and industry experts in a multi-disciplinary environment. The center facilitates the collaboration between scientific and entrepreneurial minds to turn the latest research into functional real-world applications and consumer goods.

Soy Labs recently announced a new joint research and development partnership with Missouri-based Reliv International, a direct selling company that develops, manufactures and markets nutritional products that promote optimal health and will provide greater access to the latest soy, and plant biotechnology research.

“This is a first step toward the Missouri Plant Science Center’s goal to strengthen the state’s biotechnology industry, create jobs and improve Missouri’s global economic competitiveness,” Schmidt said.

“Reliv attended the Missouri Plant Science Center last Friday, to support Gov. Nixon’s economic development efforts,” said Ryan Montgomery, Reliv’s executive vice president of worldwide sales.

“Reliv’s partnership with Soy Labs is an outgrowth of those efforts in the areas of nutritional science and technology. Our partnership will give Reliv the most advanced and effective soy ingredients on the market,” Montgomery added.

Soy Labs partnering institutions have received research funding from the National Institutes of Health, the U.S. Department of Defense, the American Institute for Cancer Research, and the Biotechnology and Biological Sciences Research Council as well as other organizations.

As one of the key pillars of the Made in Missouri Jobs Package, MOSIRA would create a funding source to spark growth in research and technology enterprises by capturing a small percentage of the growth in state revenue over a base year from a designated group of Missouri science and innovation companies.

The Missouri Technology Corporation will administer the MOSIRA funds. MTC will reinvest the MOSIRA funding through loans and other means to generate further economic growth in the science and innovation industry sectors, with emphasis on biotechnology and life sciences. Funding will be reinvested in a wide range of programs designed to create jobs, nurture start-ups, and bring science and technology companies to the state.

“Here in Missouri, we must keep our economy moving forward by embracing science and technology and investing in research and development,” said Nixon.

For more information on Soy Labs, LLC visit www.SoyLabs.com and the Missouri Plant Science Center visit www.mopsc.org .

- Photo Caption: Ryan Schmidt (left), president of Soy Labs, discusses current innovation at the Missouri Plant Science Center with Missouri’s Gov. Jay Nixon during the governor’s visit to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act as part of the Made in Missouri Jobs Package.

News Source: Soy Labs, LLC :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The natural progression of the aging process is due to cellular degeneration. Today it is widely accepted that the loss of collagen in aged skin results not only from the reduced synthesis but also due to its enhanced degradation triggered by free radicals. The repeated free radical exposure induces wrinkling of the skin, sagging of the skin, and DNA damage.

And, while many UV filters and anti-wrinkle products are offered, there are only a few products available that protect collagen – the major structural component of the skin’s connective tissue.

“Ancients understood the benefits of the white truffle – the elite of the truffle world. In early Eastern civilizations, the white truffle was not only a valued food, but also revered for its strong medicinal value. Today, we can explain this value from a scientific point of view,” says Nataly Giter, founder, E’shee Clinical Esthetic.

Research reveals that the white truffle is one of the planet’s richest sources of B vitamins – also known as “the beautifiers.” Vitamin B complex provides oxygenation to the skin, improves blood circulation and toxin removal, controls cell formation and cell life span. B-5 reduces stress and yields a smooth and lustrous skin. It also plays a key role in skin hydration, anti-aging, moisture retention and, where needed, hinders acne formation.

Truffle extracts are an excellent source of Superoxide Dismutase (SOD) – one of the most powerful cellular antioxidants. SOD is naturally occurring in the body, but it declines dramatically with age. SOD enzymes provide exceptional cellular protection against free radicals while offering anti-inflammatory properties and ultimately slowing down the aging process.

About E’shee Clinical Esthetic:
E’shee was launched in 2009 by Nataly Giter, a hands-on skin care professional with more than 20 years of experience. Through research and practical experience, she learned about the most effective ingredients for advanced skin care and became associated with Dr. Chiu, a professor from Ohio University and the first global pioneer to clone the human FGF 1 gene.

Together, with their combined connections to industry professionals, they utilized FGF 1 to create an extraordinary anti-aging product line, using 99 percent pure FGF 1 peptide – which has the best quality in the world.

For more information on E’shee Clinical Esthetic, visit: www.esheeesthetic.com or www.esheeesthetic.com/wordpress/ .

- RSS news feed for E’shee: http://send2pressnewswire.com/author/eshee-clinical-esthetic/feed .

- Photo Caption: White Truffle Radiance Cream – Diamond of Nature.

News Source: E’shee Clinical Esthetic :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

“We are very excited about rekindling our relationship with the City of Scranton’s active firefighters and police officers,” said Sara B. Picard, president of Millennium Administrators, and affiliate of Millennium Healthcare Group.

“We have a long standing history with Millennium, and we are looking forward to working collaboratively on controlling healthcare costs,” said Dave Gervasi, President of IAFF Local 60.

“We are confident Millennium will provide the quality service and immediate response our members received during their previous contractual agreement with the City 10 years ago! We are thrilled to have them back!” said Ann Marie Stulgis, President of FOP.

About Millennium Administrators, Inc.
Millennium provides employers, health insurance consultant/brokers and third party administrators stand-alone Rx programs for over 40,000 members across the country. Millennium Administrators can provide clients a self-funded or fully insured stand alone Rx program or benefits administration services that specifically meet the needs of our client.

More information: www.millennium-tpa.com .

News Source: Millennium Administrators, Inc. :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The program, designed specifically for women, is based on balanced consumption of high-quality ProtiLife protein supplements, fresh fruits, vegetables and a balanced variety of home-cooked foods. ProtiLife uses a Weekday / Weekend approach that ensures subscribers lose weight quickly and easily while acquiring the knowledge and skills needed for long-term success.

Women on the program follow a rigorous Weekday program to learn healthy, easy-to-use weight loss techniques. Then, on the two-day Weekend program, they put their learning into practice, using self-prepared food choices to replace some of their ProtiLife supplements. The program combines healthy food choices and great tasting supplements with proven learning techniques, enabling subscribers to retain healthy eating habits and maintain their goal weight permanently.

According to ProtiLife Vice President of Marketing Aldo Spensieri, the program offers the immediate results women want, plus the knowledge and tools they need for long-term success. “Permanent weight management requires learning key skills and then practicing them until they are mastered. At that point, weight management becomes second nature. Our program works because it teaches people how to do it on their own. It is easy to follow, the products taste great and they help people stay satisfied between meals. There are no tricks, no gimmicks. It is simply designed to deliver noticeable results from day one.”

The program is divided into three phases. In the Slim-down phase, individuals can lose up to 10 pounds in the first 14 days and then an average of two or three pounds per week until they reach their goal. Then, they proceed to the two-week Transition phase. In this phase, the Weekend Plan is extended over the full seven days and some previously restricted foods are re-introduced. After completing the Transition phase, they graduate to the Keep it Off! Maintenance Program, an easy-to-follow plan designed for healthy, lifelong weight management.

“One of the reasons our program is so successful is because we use high-quality proteins and well-balanced, nutrient-rich ingredients,” explains Isabelle Dupont, M.S., Director of Research & Development for ProtiLife. “Unlike some competitive products, our protein supplements are low in fat and sugar and contain eight essential amino acids as well as a healthy balance of vitamins and minerals. Also – and this is very important – we place great emphasis on flavor. Our products taste great!”

ProtiLife is a subsidiary of Ranaz (“Ranaz”) (TSX-V: RNZ) a Canadian corporation specializing in the manufacture and marketing of protein and dietary supplements. Ranaz Corporation distributes product in 14 countries.

For more information on the ProtiLife program visit www.protilife.com .

News Source: ProtiLife Distribution Inc. :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

An improvement on existing 96-Well systems, the Multi-Tier Plate can be built using spacers to hold vial capacities of 0.5ml, 1.0ml, 1.5ml and 2.0ml depending on the height limitations of the instrument. Replacement vials can be purchased in a vial loader format which is a fast and convenient choice for loading vials into the base plate.

“Just peel away the packaging of the vial loader and place an empty base plate on the top of the vial loader. Invert the entire unit and the plate is ready to use,” says Clifton Hitchner, vice president, Laboratory Supply Distributors Corp.

The Multi-Tier Micro Plate (link to PDF) System allows for the use of individual vials of different heights and volumes, providing for maximum diversity.

Additionally, many assays require heating or cooling of the vials to simulate in-vitro conditions or for temperature sensitive experiments. The new, open bottom design allows the base plate to be immersed in heating or cooling fluids to provide for total fluid contact with the vials. In turn, this allows for a uniform transfer of heat or cold to and from the vials.

Primarily, these systems are ideal for experimental and sorbent assays; drug discovery; drug metabolism research; combinatorial chemistry; high-throughput screening (HTS); and liquid chromatography with tandem mass spectrometry (LC-MS-MS).

In addition to the volume choices available, labs may also choose between 9mm plastic or glass inserts with conical or flat bottoms. The plate may also be fixed height or adjusted to height limitation of analytical instrument.

Spacers build adjustable height to support different-sized inserts. And, plate cover locks the liner in place, prevents vial pullout and provides a secondary sealing system.

For more information, visit: www.LSDCorp.com .

About Laboratory Supply Distributors Corp.:
Laboratory Supply Distributors Corp. is a worldwide supplier of unique and innovative products for the analytical, environmental, research, life science, pharmaceutical and academic communities.

Products range from glass and plastic vials, screw-thread closures, aluminum seals, and various types of limited volume inserts.

Its products deliver reliable performance while expediting and simplifying the analysis process. In business for nearly 20 years, Laboratory Supply Distributors Corp. provides its customers with tools that can expand capabilities, increase lab efficiency, reduce cost and simplify the work process.

News Source: Laboratory Supply Distributors Corp. :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .